The Global Tribune

BK virus (BKV) Infection Pipeline Analysis Shows Tremendous Growth Opportunities for the Coming Years | AlloVir, Amplyx Pharmaceutical, SL VAXiGEN, Hybridize Therapeutics & Others

 Breaking News
  • No posts were found

BK virus (BKV) Infection Pipeline Analysis Shows Tremendous Growth Opportunities for the Coming Years | AlloVir, Amplyx Pharmaceutical, SL VAXiGEN, Hybridize Therapeutics & Others

February 24
07:40 2021
BK virus (BKV) Infection Pipeline Analysis Shows Tremendous Growth Opportunities for the Coming Years | AlloVir, Amplyx Pharmaceutical, SL VAXiGEN, Hybridize Therapeutics & Others

BK virus (BKV) Infection Pipeline


BK virus (BKV) Infection Pipeline Insight, 2021” by DelveInsight highlights the details around the NMIBC pipeline scenario, unmet needs, and Non-Muscle Invasive Bladder Cancer therapeutic assessment of the key pipeline therapies. 


BK virus (BKV) Infection– The BK virus was first isolated from the urine of a renal transplant recipient with ureteric stenosis in 1971. BK virus is one of 13 known polyomaviruses. Antibodies to BKV are found in approximately 80 to 90 percent of adults worldwide, indicating previous infection or exposure to the virus. Initial infection with BKV is usually asymptomatic or associated with a mild flu-like illness. After primary infection, BKV remains inactive, or latent, in kidney and bladder. A weakened immune system may result in BKV reactivation and cause serious disease. In patients who have had kidney transplant, BKV can lead to the loss of the transplanted kidney.

In the absence of effective treatment, reduction of immunosuppression is recommended; however, lowering of the immunosuppression can lead to acute organ rejection. BKV reactivation in the bladder can cause hemorrhagic cystitis. Severe cases require bladder irrigation, clot evacuation, blood transfusion, stenting and nephrostomy. There are currently no approved treatments for renal nephropathy or hemorrhagic cystitis caused by BKV.


Some of the BK virus (BKV) Infection Companies:

  • AlloVir
  • Amplyx Pharmaceuticals
  • Hybridize Therapeutics
  • And Many Others


To learn more about BK virus (BKV) Infection Drugs, request  BK virus (BKV) Infection Drugs Pipeline Sample Report 



Some of the BK virus (BKV) Infection drugs covered:

  • ALVR-105
  • MAU868
  • SL-V10
  • And Many Others


Request Sample Page @ BK virus (BKV) Infection Marketed Therapies and Treatment Approaches and get a comprehensive understanding of the BK virus (BKV) Infection therapeutic outlook


BK virus (BKV) Infection Diagnosis

BK virus is detectable in both blood and urine. After BK reactivation, the virus is first detectable in the urine, with viremia developing several weeks later. BK detection by real-time PCR of plasma is very sensitive and specific for the development of BKVN. BKV shedding in the urine is common and can occur in up to 30% of renal transplant recipients. Urine can be screened for BK by cytology or by quantification of urine BK DNA by PCR. Haufen are icosahedral aggregates of polyomavirus particles and Tamm-Horsfall protein that can be detected in the urine of kidney transplant patients with BKVN using negative-staining electron microscopy. Renal biopsy remains the gold standard for the diagnosis of BKVN. It is recommended in patients with a high level of BKV (>4 log copies/mL), with or without an elevation in serum creatinine.


BK virus (BKV) Infection Treatment

The mainstay of treatment for BK virus nephropathy is to decrease the immunosuppression, as there is currently no specific antiviral for BK virus. Clearance of BK viremia can be indicative of nephropathy resolution.


To learn more about BK virus (BKV) Infection Drugs Development, request BK virus (BKV) Infection Drugs Pipeline Sample Report 


Table of Contents:

1. Report Introduction

2. BK virus (BKV) Infection Overview

3. BK virus (BKV) Infection Current Treatment Patterns

4. BK virus (BKV) Infection – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. BK virus (BKV) Infection Late Stage Products (Phase-III)

7. BK virus (BKV) Infection Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. BK virus (BKV) Infection Discontinued Products

13. BK virus (BKV) Infection Product Profiles

13.1. AlloVir: ALVR-105

13.1.1. Product Description Product Overview Mechanism of action

13.1.2. Research and Development Clinical Studies

13.1.3. Product Development Activities Collaboration Agreements Acquisition Patent Detail

13.1.4. Tabulated Product Summary General Description Table

Detailed information in the report!

And Many Others…

14. BK virus (BKV) Infection Key Companies

15. BK virus (BKV) Infection Key Products

16. Dormant and Discontinued Products

17. BK virus (BKV) Infection Unmet Needs

18. BK virus (BKV) Infection Future Perspectives

19. BK virus (BKV) Infection Analyst Review  

20. Appendix

21. Report Methodology

About DelveInsight 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

DelveInsght’s Competitive Intelligence Service includes a multidimensional coverage, helping to keep track of competitors and gain traction in the dynamic market by overcoming the challenges and expediting business growth through a strategic and tactical approach.   

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States